Significant advances in the treatment of pulmonary arterial hypertension (PAH) have
occurred over the last 10 years, starting with the approval of epoprostenol in 1998 …

Objectives To investigate survival in patients with Eisenmenger syndrome based on a
systematic review of the literature and reanalysis of data. We specifically tested the …

Background—Eisenmenger syndrome is characterized by the development of pulmonary
arterial hypertension with consequent intracardiac right-to-left shunt and hypoxemia in …

BACKGROUND: Bosentan, an oral endothelin ETA/ETB receptor antagonist, improves
hemodynamics and exercise capacity in patients with Eisenmenger syndrome but longer …

BACKGROUND: To test the hypothesis that chronic sildenafil treatment has similar
functional and hemodynamic effects in patients with severe pulmonary arterial hypertension …

Background Although sildenafil has been shown to be safe and effective in idiopathic
pulmonary arterial hypertension (PAH) and PAH related to connective tissue disease, its …

There are limited data on the effect of iloprost therapy in patients with Eisenmenger
syndrome (ES). The aim of our study was to evaluate the effect of inhaled iloprost therapy on …

Eisenmenger syndrome is the most severe form of pulmonary arterial hypertension and
arises on the basis of congenital heart disease with a systemic-to-pulmonary shunt. Due to …

Pulmonary hypertension (PH) refers to elevated pulmonary artery (PA) pressure (PAP),
defined as mean PAP≥ 25 mm Hg. PH is not synonymous with pulmonary arterial …

Objectives Although a significant proportion of patients with cyanotic congenital heart
disease are thrombocytopaenic, its prevalence and clinical significance in adults with …